Could a cystic fibrosis drug help brain bleed survivors walk again?

NCT ID NCT06723717

Recruiting now Disease control Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving dornase alfa (a drug already used for cystic fibrosis) daily for up to 14 days after a brain bleed from a ruptured aneurysm can help people recover better. The goal is to see if more patients can live independently at 6 months. The trial will enroll 304 adults and compares the drug to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dornase alfa (Pulmozyme®)
What this could lead to: If it works, this could offer a new treatment to prevent delayed brain damage after a ruptured aneurysm, helping more survivors regain independence.
What could go wrong: This is a Phase 2 trial with 304 participants, so results are still early. The drug has not been proven for this condition, and there is no guarantee it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DELAYED CEREBRAL ISCHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage brain ischemia subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DELAYED CEREBRAL ISCHEMIA RUPTURED ANEURYSM OF INTRACRANIAL ARTERY SAH (SUBARACHNOID HEMORRHAGE)

Contacts and locations

Locations

CHU Poitiers
RECRUITING

Poitiers, Poitiers, 86000, France
CHU Strasbourg
RECRUITING

Strasbourg, Strasbourg, France
CHU de Grenoble
RECRUITING

Grenoble, Grenoble, France
CHU de Montpellier
RECRUITING

Montpellier, Montpellier, France
HCL de Lyon
RECRUITING

Lyon, Lyon, 69002, France
Hôpital FOCH
RECRUITING

Suresnes, Île-de-France Region, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.